Alerta

METHODS AND COMPOSITIONS FOR TAUOPATHY DIAGNOSIS AND TREATMENT

Resumen de: US2025298039A1

This disclosure relates to methods for diagnosing and treating a tauopathy, e.g., Alzheimer's disease, in a subject, the methods comprising, in part, identifying one or more post-translation modifications (PTMs) in the subject.

COMPOUNDS AND METHODS TARGETING INTERLEUKIN-34

Resumen de: US2025296997A1

The present disclosure relates to IL-34 antibodies, compositions comprising the same, and methods of using the antibodies and or compositions thereof for treating immune-mediated diseases such as neurodegenerative diseases, for example Alzheimer's Disease or a tauopathy disease.

ANTIBODIES TO a-SYNUCLEIN AND USES THEREOF

Resumen de: AU2025226709A1

The present invention relates to an anti-alpha-synuclein antibody preferentially recognizing alpha-synuclein aggregates and a use of detection, diagnosis, and/or treatment or prevention of various diseases caused by accumulation of alpha-synuclein aggregates, or their related symptom diseases by using the anti-alpha-synuclein antibody. The present invention relates to an anti-alpha-synuclein antibody preferentially recognizing alpha-synuclein aggregates and a use of detection, diagnosis, and/or treatment or prevention of various diseases caused by accumulation of alpha-synuclein aggregates, or their related symptom diseases by using the anti-alpha-synuclein antibody. ep e p h e p r e s e n t i n v e n t i o n r e l a t e s t o a n a n t i - a l p h a - s y n u c l e i n a n t i b o d y p r e f e r e n t i a l l y r e c o g n i z i n g a l p h a - s y n u c l e i n a g g r e g a t e s a n d a u s e o f d e t e c t i o n , d i a g n o s i s , a n d o r t r e a t m e n t o r p r e v e n t i o n o f v a r i o u s d i s e a s e s c a u s e d b y a c c u m u l a t i o n o f a l p h a - s y n u c l e i n a g g r e g a t e s , o r t h e i r r e l a t e d s y m p t o m d i s e a s e s b y u s i n g t h e a n t i - a l p h a - s y n u c l e i n a n t i b o d y

Multiplexed assay and methods of use thereof

Resumen de: AU2025226659A1

The present disclosure provides methods for blood-based examination useful to identify subjects with Aβ amyloidosis and/or to identify subjects who should or should not undergo further testing or treatment for Aβ amyloidosis, as well as methods for treating subjects diagnosed with Aβ amyloidosis by the methods disclosed herein. The present disclosure provides methods for blood-based examination useful to identify subjects with Aß amyloidosis and/or to identify subjects who should or should not undergo further testing or treatment for Aß amyloidosis, as well as methods for treating subjects diagnosed with Aß amyloidosis by the methods disclosed herein. ep h e p r e s e n t d i s c l o s u r e p r o v i d e s m e t h o d s f o r b l o o d - b a s e d e x a m i n a t i o n u s e f u l t o e p i d e n t i f y s u b j e c t s w i t h ß a m y l o i d o s i s a n d o r t o i d e n t i f y s u b j e c t s w h o s h o u l d o r s h o u l d n o t u n d e r g o f u r t h e r t e s t i n g o r t r e a t m e n t f o r ß a m y l o i d o s i s , a s w e l l a s m e t h o d s f o r t r e a t i n g s u b j e c t s d i a g n o s e d w i t h ß a m y l o i d o s i s b y t h e m e t h o d s d i s c l o s e d h e r e i n

MMP-14 POTENCY ASSAY FOR MESENCHYMAL STEM CELLS

Resumen de: WO2025199451A2

Compositions and methods are disclosed herein for the treatment of Alzheimer's disease with allogeneic mesenchymal stem cells (MSCs). The methods of treatment involve an administration of a composition of allogeneic mesenchymal stem cells to a subject in need thereof, wherein the effectiveness of the treatment methods can be determined through the measurement of specific biomarkers and improved cognitive or quality-of-life function.

COMPOSITIONS AND METHODS FOR TREATMENT AND PREVENTION OF ALZHEIMER'S DISEASE

Resumen de: WO2025199495A1

The present invention provides methods and compositions for reducing internalization and/or trafficking of tan in neuronal cells comprising contacting the cells with an effective amount of VLDL receptor antagonist. The invention further provides a method of treating or preventing Alzheimer's disease in a subject in need thereof, comprising administering to the subject an effective amount of a VLDL receptor antagonist.

METHODS OF TREATING EPILEPSY

Resumen de: US2025295643A1

In various aspects and embodiments the invention provides a method of treating epilepsy in a subject in need thereof, the method comprising providing to the subject an effective amount of an FLNA modulator. In various embodiments, the FLNA modulator is PTI-125 or kartogenin. In various embodiments, the epilepsy is epilepsy associated with focal cortical dysplasia (FCD) type II or tuberous sclerosis complex (TSC).

BIOMARKER PANEL FOR BRAIN SPECIFIC ABNORMAL NEUROLOGICAL CONDITIONS USING BIOFLUID SAMPLES

Nº publicación: EP4619763A1 24/09/2025

Solicitante:

GRYPHON BIO INC [US]
Gryphon Bio, Inc

Resumen de: WO2024107948A1

A process for determining an extent of a central nervous system (CNS) specific neurological condition in a subject including collecting a biological sample of biofluid from the subject and measuring a quantity of a first biomarker, or metabolite of or mRNA corresponding to, the first biomarker from the sample from a dried spot or through a microfluidic device. The biofluid is capillary blood or saliva, which affords ease of collection advantages that are attractive for field-, hospital-, and home-based environments. The process being useful in the diagnosis, care, and management of brain specific abnormal neurological conditions in general, and in particular, to traumatic brain injury (TBI) and (TBI-induced) Alzheimer's disease (AD) and Alexander disease, in which a GFAP mutation is implicated in white matter deterioration.